uric acid has been researched along with Acute Relapsing Multiple Sclerosis in 10 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The bilirubin and UA levels were lower in CIS and RRMS patients than in control group, whether male or female (p < 0." | 5.39 | Association of serum bilirubin and uric acid levels changes during neuroinflammation in patients with initial and relapsed demyelination attacks. ( Dunjic, O; Ljubisavljevic, S; Milojkovic, M; Pavlovic, D; Stojanov, D; Stojanovic, I; Vojinovic, S, 2013) |
| "Uric acid (UA) is a hydrophilic antioxidant product associated with multiple sclerosis (MS)." | 2.78 | Serum uric acid level in patients with relapsing-remitting multiple sclerosis. ( Aghaei, M; Ashtari, F; Bahar, M; Zahed, A, 2013) |
| "Uric acid has neuroprotective effects in experimental models including encephalomyelitis and appears to be involved in multiple sclerosis." | 2.75 | Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon beta in relapsing- remitting Multiple Sclerosis (ASIIMS) trial. ( D'hooghe, MB; De Deyn, PP; Gonsette, RE; Guillaume, D; Medaer, R; Michotte, A; Seeldrayers, P; Sindic, C, 2010) |
| "Uric acid was successfully used in both, prevention and treatment of the animal model of multiple sclerosis (MS)." | 2.72 | Therapeutic value of serum uric acid levels increasing in the treatment of multiple sclerosis. ( Toncev, G, 2006) |
| "The bilirubin and UA levels were lower in CIS and RRMS patients than in control group, whether male or female (p < 0." | 1.39 | Association of serum bilirubin and uric acid levels changes during neuroinflammation in patients with initial and relapsed demyelination attacks. ( Dunjic, O; Ljubisavljevic, S; Milojkovic, M; Pavlovic, D; Stojanov, D; Stojanovic, I; Vojinovic, S, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ashtari, F | 1 |
| Bahar, M | 1 |
| Aghaei, M | 1 |
| Zahed, A | 1 |
| Ljubisavljevic, S | 1 |
| Stojanovic, I | 1 |
| Vojinovic, S | 1 |
| Milojkovic, M | 1 |
| Dunjic, O | 1 |
| Stojanov, D | 1 |
| Pavlovic, D | 1 |
| Moccia, M | 1 |
| Lanzillo, R | 1 |
| Costabile, T | 1 |
| Russo, C | 1 |
| Carotenuto, A | 1 |
| Sasso, G | 1 |
| Postiglione, E | 1 |
| De Luca Picione, C | 1 |
| Vastola, M | 1 |
| Maniscalco, GT | 1 |
| Palladino, R | 1 |
| Brescia Morra, V | 1 |
| Markowitz, CE | 1 |
| Spitsin, S | 1 |
| Zimmerman, V | 1 |
| Jacobs, D | 1 |
| Udupa, JK | 1 |
| Hooper, DC | 1 |
| Koprowski, H | 1 |
| Gonsette, RE | 1 |
| Sindic, C | 1 |
| D'hooghe, MB | 1 |
| De Deyn, PP | 1 |
| Medaer, R | 1 |
| Michotte, A | 1 |
| Seeldrayers, P | 1 |
| Guillaume, D | 1 |
| Miller, E | 1 |
| Walczak, A | 1 |
| Saluk, J | 1 |
| Ponczek, MB | 1 |
| Majsterek, I | 1 |
| Oliveira, SR | 1 |
| Kallaur, AP | 1 |
| Simão, AN | 1 |
| Morimoto, HK | 1 |
| Lopes, J | 1 |
| Panis, C | 1 |
| Petenucci, DL | 1 |
| da Silva, E | 1 |
| Cecchini, R | 1 |
| Kaimen-Maciel, DR | 1 |
| Reiche, EM | 1 |
| Toncev, G | 2 |
| Constantinescu, CS | 1 |
| Freitag, P | 1 |
| Kappos, L | 1 |
| Milicic, B | 1 |
| Toncev, S | 1 |
| Samardzic, G | 1 |
5 trials available for uric acid and Acute Relapsing Multiple Sclerosis
| Article | Year |
|---|---|
Serum uric acid level in patients with relapsing-remitting multiple sclerosis.
Topics: Adolescent; Adult; Case-Control Studies; Female; Humans; Male; Middle Aged; Multiple Sclerosis, Rela | 2013 |
The treatment of multiple sclerosis with inosine.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Brain; CD4 Lymphocyte Count; Central Nervous Sy | 2009 |
Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon beta in relapsing- remitting Multiple Sclerosis (ASIIMS) trial.
Topics: Adult; Anti-Inflammatory Agents; Belgium; Disability Evaluation; Disease Progression; Double-Blind M | 2010 |
Therapeutic value of serum uric acid levels increasing in the treatment of multiple sclerosis.
Topics: Administration, Oral; Adolescent; Adult; Female; Humans; Inosine; Male; Middle Aged; Multiple Sclero | 2006 |
Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis.
Topics: Adjuvants, Immunologic; Adult; Antioxidants; Female; Glatiramer Acetate; Humans; Immunosuppressive A | 2000 |
5 other studies available for uric acid and Acute Relapsing Multiple Sclerosis
| Article | Year |
|---|---|
Association of serum bilirubin and uric acid levels changes during neuroinflammation in patients with initial and relapsed demyelination attacks.
Topics: Adolescent; Adult; Bilirubin; Brain; Demyelinating Diseases; Disability Evaluation; Disease Progress | 2013 |
Uric acid in relapsing-remitting multiple sclerosis: a 2-year longitudinal study.
Topics: Adolescent; Adult; Analysis of Variance; Cognition Disorders; Disability Evaluation; Disease Progres | 2015 |
Oxidative modification of patient's plasma proteins and its role in pathogenesis of multiple sclerosis.
Topics: Adult; Blood Proteins; Blood-Brain Barrier; Carbon; Disease Progression; Female; Humans; Male; Middl | 2012 |
Oxidative stress in multiple sclerosis patients in clinical remission: association with the expanded disability status scale.
Topics: Adult; Disability Evaluation; Disabled Persons; Female; Humans; Luminescence; Male; Mediator Complex | 2012 |
Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction.
Topics: Adolescent; Adult; Blood-Brain Barrier; Disability Evaluation; Female; Gadolinium; Humans; Magnetic | 2002 |